MW Advisory LLC Makes New $601,000 Investment in Novartis AG $NVS

MW Advisory LLC bought a new stake in shares of Novartis AG (NYSE:NVS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 3,834 shares of the company’s stock, valued at approximately $601,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after buying an additional 2,666 shares during the period. AQR Capital Management LLC grew its position in shares of Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after buying an additional 11,444 shares during the period. Empowered Funds LLC bought a new stake in shares of Novartis in the 1st quarter valued at about $1,764,000. Sivia Capital Partners LLC increased its stake in shares of Novartis by 48.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares during the last quarter. Finally, Schnieders Capital Management LLC. acquired a new stake in shares of Novartis in the 2nd quarter valued at approximately $202,000. 13.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on NVS. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Citigroup reiterated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Novartis presently has an average rating of “Hold” and a consensus price target of $141.20.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reported that remibrutinib met the primary endpoint in two Phase 3 trials for relapsing multiple sclerosis. The result supports the potential expansion of the drug beyond its existing development opportunities. Novartis Remibrutinib Phase 3 Trial Results
• Neutral Sentiment: Novartis’ recent Basel-related move and a reported multibillion-dollar investment to improve how an existing medicine is delivered point to a shift in strategic priorities. The initiative could support product differentiation and lifecycle management, although its financial impact is not yet clear. Novartis Basel Strategic Move
• Neutral Sentiment: Options traders purchased a large volume of Novartis put contracts, signaling increased near-term hedging or bearish speculation. This reflects market sentiment rather than a change in the company’s fundamentals. Novartis Put Option Activity
• Negative Sentiment: Novartis and partner Ionis Pharmaceuticals said pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial. The setback weakens the outlook for a closely watched treatment targeting lipoprotein(a), a major potential growth opportunity in cardiovascular medicine. Pelacarsen Late-Stage Trial Failure
• Negative Sentiment: Novartis paused eight experimental rap-cel CAR-T trials after three patient deaths linked to severe immune reactions. The safety issue threatens development of the company’s autoimmune and neurological cell-therapy programs and raises regulatory and disclosure concerns. Novartis CAR-T Trial Halt
• Negative Sentiment: Erste Group Bank lowered its earnings estimates for Novartis, adding pressure to expectations for future results. Combined with the pelacarsen failure and CAR-T safety pause, the revisions reinforce concerns about pipeline execution. Erste Group Cuts Novartis Earnings Estimates

Novartis Stock Down 1.9%

Shares of Novartis stock opened at $159.95 on Friday. The business’s 50 day simple moving average is $155.74 and its 200 day simple moving average is $153.78. Novartis AG has a 52-week low of $121.57 and a 52-week high of $170.46. The firm has a market cap of $305.21 billion, a PE ratio of 24.13, a P/E/G ratio of 3.18 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. On average, analysts predict that Novartis AG will post 8.84 earnings per share for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.